Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest announcement is out from Cormedix ( (CRMD) ).
On September 2, 2025, CorMedix Inc. announced the completion of its acquisition of Melinta Therapeutics LLC, a move that significantly expands its commercial product portfolio with seven marketed drug products. This acquisition is expected to enhance CorMedix’s revenue base and drive future growth, with revised 2025 revenue guidance estimated between $325 million and $350 million. The merger is anticipated to be accretive to earnings per share in the near term, with expected annual run-rate synergies of $35 to $45 million. Additionally, CorMedix announced new leadership appointments, including Susan Blum as Chief Financial Officer, Elizabeth Hurlburt as Chief Operating Officer, and Matthew David as Chief Business Officer, effective as of the closing date.
The most recent analyst rating on (CRMD) stock is a Buy with a $21.00 price target. To see the full list of analyst forecasts on Cormedix stock, see the CRMD Stock Forecast page.
Spark’s Take on CRMD Stock
According to Spark, TipRanks’ AI Analyst, CRMD is a Neutral.
Cormedix’s overall stock score is influenced by a challenging financial position, marked by ongoing losses and negative cash flows. Despite technical indicators showing potential downward pressure, the recent earnings call provides a positive outlook with record-breaking revenue and strategic growth initiatives. However, valuation concerns and operational challenges remain significant obstacles.
To see Spark’s full report on CRMD stock, click here.
More about Cormedix
CorMedix Inc. is a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases. Following its acquisition of Melinta Therapeutics LLC, CorMedix is commercializing a portfolio of anti-infective products, including DefenCath® for catheter-related bloodstream infections and several other products for infectious diseases.
Average Trading Volume: 2,630,753
Technical Sentiment Signal: Buy
Current Market Cap: $1.11B
See more insights into CRMD stock on TipRanks’ Stock Analysis page.